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Abstract
Aims—To investigate the hypothesis that alteration in histone acetylation/deacetylation triggers 
aberrant STAT1/MyD88 expression in macrophages from diabetics. Increased STAT1/MyD88 
expression is correlated with sterile inflammation in type 1 diabetic (T1D) mice.
Methods—To induce diabetes, we injected low-doses of streptozotocin in C57BL/6 mice. 
Peritoneal or bone marrow-differentiated macrophages were cultured in 5 mM (low) or 25 mM 
(high glucose). ChIP analysis of macrophages from nondiabetic or diabetic mice was performed to 
determine acetylation of lysine 9 in histone H3 in MyD88 and STAT1 promoter regions. 
Macrophages from diabetic mice were treated with the histone acetyltransferase inhibitor 
anacardic acid (AA), followed by determination of mRNA expression by qPCR.
Results—Increased STAT1 and MyD88 expression in macrophages from diabetic but not naive 
mice cultured in low glucose persisted for up to 6 days. Macrophages from diabetic mice exhibited 
increased activity of histone acetyltransferases (HAT) and decreased histone deacetylases (HDAC) 
activity. We detected increased H3K9Ac binding to Stat1/Myd88 promoters in macrophages from 
T1D mice and AA in vitro treatment reduced STAT1 and MyD88 mRNA expression.
Conclusions/interpretation—These results indicate that histone acetylation drives elevated 
Stat1/Myd88 expression in macrophages from diabetic mice, and this mechanism may be involved 
in sterile inflammation and diabetes comorbidities.
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Introduction
Sterile inflammation, a chronic low-grade systemic inflammation, is the main cause of 
comorbidities such as retinopathy and nephropathy that are associated with diabetes. Sterile 
inflammation is associated with increased systemic levels of pro-inflammatory cytokines, 
including elevated interleukin (IL)-1β, which drives several comorbidities (Chen and Nunez 
2010, Filgueiras, Serezani et al. 2015). The IL-1 receptor is a member of the Toll-Like 
Receptor (TLR) family, and like most TLR receptors, its signaling pathway is dependent on 
the adaptor molecule Myeloid Differentiation factor 88 (MyD88) (Takeuchi and Akira 
2002).
We have previously shown that macrophages from type 1 diabetic (T1D) mice express 
increased levels of MyD88 and its transcription factor Signal Transducer and Activator of 
Transcription (STAT) 1, which is dependent on the production of the inflammatory lipid 
mediator leukotriene B4 (LTB4). Our results showed that the elevated systemic levels of 
LTB4 found in T1D mice promote the binding of STAT1 to MyD88 promoter, leading to 
enhanced MyD88 expression in macrophages. Increased STAT/MyD88 expression 
potentiates macrophages TLR/IL1β receptors response. Moreover, the sterile inflammation 
in T1D mice characterized by increased systemic levels of TNF-α and IL-1β, is dependent 
on the LTB4-induced STAT1/MyD88 axis (Filgueiras, Brandt et al. 2015). Because some 
long-term diabetes complications develop even in insulin-treated patients who exhibit 
improved glucose control, it is thought that epigenetic mechanisms associated with diabetes 
are responsible, a process characterized as “metabolic memory” (Ceriello 2009, Cooper and 
El-Osta 2010).
Epigenetic mechanisms are typically mediated through chromatin dynamics. Chromatin is a 
highly organized structure in which DNA is wrapped around a histone octamer unit. The 
structure of chromatin plays a central role in controlling transcription of genes. Chromatin 
structure is dynamic, and is tightly regulated by several epigenetic mechanisms including 
histone modifications. Histones can be acetylated at multiple lysine residues, and the 
specific combination of acetylated lysines determines the accessibility of the DNA template 
to the transcriptional machinery enabling gene expression. Thus, acetylation is generally 
associated with increased transcriptional activity. Histone acetyltransferases (HATs) mediate 
histone acetylation, whereas, histone deacetylases (HDACs) reduce transcription by 
removing acetyl groups from lysine residues (Kouzarides 2007, Li, Carey et al. 2007).
Accumulating evidence suggests that in both diabetic animals and human patients, key 
aspects of regulating the transcription of genes involved in the development of diabetes 
comorbidities are dependent on epigenetic mechanisms (Reddy, Zhang et al. 2015). Thus, 
we sought to determine the contribution of epigenetic histone acetylation in increased 
STAT-1/MyD88 expression associated with development of diabetes in T1D mice.
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Material and Methods
Animals
Eight-week-old male C57BL/6 mice were maintained according to National Institutes of 
Health guidelines for the use of experimental animals with the approval of the Indiana 
University Committees for the Use and Care of Animals and Ethical Committee for Animal 
Research of the Institute of Biomedical Sciences of the University of São Paulo.
Diabetes induction
T1D was chemically induced by five sequential daily intraperitoneal injections of a freshly 
prepared solution of streptozotocin (40 mg/kg) (Filgueiras, Brandt et al. 2015). Blood 
glucose concentrations were measured 10 days after the last injection of STZ using 
OneTouch Select glucometer and test strips (Life Scan). Mice were considered diabetic 
when blood glucose concentrations reached >300 mg/dl on two consecutive days. The 
control group received five intraperitoneal injections of the vehicle.
Macrophage isolation and differentiation
Resident peritoneal macrophages were isolated by lavage of the peritoneal cavity with cold 
PBS and cultured as described (Serezani, Lewis et al. 2011). Peritoneal macrophages were 
treated with the noncompetitive and specific inhibitor of class I and II histone deacetylases 
trichostatin A (TSA -10 µM) (Vigushin, Ali et al. 2001) or the p300 and PCAF histone 
acetyltransferase inhibitor anacardic acid (AA- 10 µM or 30 µM) (Mai, Rotili et al. 2006) for 
24 hours followed by RNA isolation.
Bone marrow-derived macrophages were obtained as previously described (Davies and 
Gordon 2005), with minor modifications. In brief, femurs were flushed with DMEM 
(Dulbecco’s modified eagle medium containing 2mM l-glutamine, 100U/mL penicillinG, 
and 100mg/mL streptomycin, all from Gibco, Long Island, NY, USA), using a 26-G ×½ G 
needle. Cells were grown in high (25 mM) or low (5 mM) glucose DMEM containing 20 
ng/mL M-CSF (Pepro Tech, Brazil) and 5% of heat-inactivated fetal calf serum (FCS), 
incubated at 37°C in 5% CO2. On day 3, new fresh DMEM with M-CSF (20 ng/mL) was 
added. A monolayer of macrophages was scraped on day 6 (96% of the cells were positive 
for CD11b and F4/80 (Ferracini, Rios et al. 2013).
RNA isolation and qPCR
Total RNA from cultured cells was isolated using Direct-zol RNA MiniPrep (Zymo 
Research) according to the manufacturer’s instruction. Complementary DNA (cDNA) was 
synthesized using a reverse transcription system (RevertAid First Strand cDNA Synthesis 
Kit, Thermo Scientific) and qPCR was performed with Fast SYBR® Green Master Mix 
(Applied Biosystems) containing primers for Myd88, Stat1, Stat3 and Hprt (all from 
Integrated DNATechnologies) on the Step One Plus Real-Time PCR Detection System 
(Applied Biosystems). Relative expression was calculated using the comparative threshold 
cycle (Ct) and calculated relative to control or wild type (DDCt method).
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ChIP assay
ChIP assays were performed with a SimpleChIP Enzymatic Chromatin IP Kit (Cell 
Signaling Technology) according to the manufacturer’s protocol. Cells were fixed and cross-
linked with 1% formaldehyde, and chromatin was digested with micrococcal nuclease and 
sonicated (UP100H; Hielscher) to obtain DNA fragments of about 150 to 900 base pairs. 
The resulting cross-linked chromatin preparation was subsequently enriched by 
immunoprecipitation with anti-H3K9Ac (1:100; Cell Signaling Technology) or anti- di-
methyl-H3K79 (1:100; Cell Signaling Technology) antibodies. Normal rabbit 
immunoglobulin G (IgG) (1:100) and anti–histone H3 (1:50) antibodies (Cell Signaling 
Technology) were used as negative and positive controls, respectively. For each 
immunoprecipitation, 20 mg of cross-linked chromatin was diluted in ChIP buffer to a final 
volume of 0.5 ml, mixed with indicated antibodies, and incubated for 4 hours at room 
temperature with rotation. Immune complexes were captured using 30 ml of ChIP-Grade 
Protein G Magnetic Beads (Cell Signaling Technology) according to the manufacturer’s 
protocol. The chromatin was eluted from the beads by adding elution buffer and incubating 
at 65°C for 30 min followed by digestion with proteinase K for 2 hours at 65°C. 
Subsequently, DNA was purified using spin columns (Qiagen), and samples were subjected 
to real-time PCR using the primers for different promoter regions of Stat1, Stat3 or Myd88.
Results
Persistent increase in MyD88 and STAT1 gene expression in macrophages from diabetic 
mice
We have previously shown that peritoneal macrophages from T1D mice exhibited higher 
expression of MyD88 and STAT1 than macrophages from nondiabetic animals (Filgueiras, 
Brandt et al. 2015), although the mechanisms remain unknown. Initially, we sought to 
determine whether the observed increase in STAT1/MyD88 expression in macrophages from 
T1D mice could be restored to normal levels by culturing cells in low glucose medium. The 
results showed that expression was not normalized, as increased STAT1/MyD88 mRNA and 
protein expression persisted for at least 6 days in T1D macrophages incubated in low 
glucose medium (Fig 1A to C). Because diabetes skews macrophages toward pro-
inflammatory phenotype (Kanter, Kramer et al. 2012, Filgueiras, Brandt et al. 2015), we also 
analyzed iNOS expression and found that after 6 days in low glucose medium, macrophages 
from T1D mice still presented increased iNOS expression (Fig 1C).
We then tested whether increased Stat1/Myd88 expression by macrophages in T1D mice 
was initiated in precursor cells in bone marrow or was restricted to mature macrophages. 
When differentiated in low glucose medium, macrophages derived from bone marrow of 
T1D mice exhibited increased Stat1/Myd88 levels, whereas, macrophages differentiated 
from bone marrow of nondiabetic mice did not. When differentiated in high glucose medium 
Stat1/Myd88 expression by macrophages differentiated from bone marrow of T1D mice was 
not higher than expression by T1D macrophages differentiated in low glucose medium. 
However, Stat1/Myd88 expression by macrophages differentiated from bone marrow of 
nondiabetic mice in high glucose medium was higher than expression by macrophages 
differentiated in low glucose (Fig 1D and E). This was not observed when manitol was 
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added for osmotic control (Fig 1F and G), indicating that indeed hyperglycemia promotes 
expression of these genes.
Together these results suggest that diabetic condition promote epigenetic mechanisms that 
induce a persistent increase in macrophage Stat1 and Myd88 gene expression.
Imbalance in HAT/HDAC activities in macrophages from T1D mice correlates with 
increased MyD88 expression
To address the possibility that these effects of glucose levels during macrophage 
differentiation on STAT1/MyD88 expression involved epigenetic regulation, we investigated 
the activity of enzymes involved in histone acetylation. We found that total HAT activity was 
increased and total HDAC activity was decreased in macrophages from T1D mice (Fig 2A) 
relative to normal macrophages. When we treated macrophages from nondiabetic mice with 
the potent HDAC activity inhibitor Trichostatin A (TSA), which favors histone acetylation 
(Vigushin, Ali et al. 2001), we found that expression of Myd88 (Fig 2B) and Stat1 (Fig 2C) 
were enhanced. This was not observed when T1D macrophages were treated with TSA (Fig. 
1D and E). We observed a similar effect when nondiabetic mice were treated in vivo with 
TSA (Fig. 2F). These results are consistent with the possibility that epigenetic histone 
acetylation drives increased Stat1/Myd88 expression in T1D.
Acetylation in lysine 9 residues of histone H3 on Myd88 and Stat1 promoter region in 
macrophages from diabetic mice
We next determined whether the lysine 9 residues of histone H3 (H3K9) associated with 
promoter regions of Myd88 and Stat1 were acetylated in macrophages during T1D; 
acetylation of H3K9 (H3K9Ac) is a key histone modification involved in transcription 
(Reddy, Zhang et al. 2015). In macrophages from T1D but not nondiabetic mice, we found 
H3K9Ac in 2 different regions of the MyD88 promoter (Fig. 3A) and in 3 different regions 
of the Stat1 promoter (Fig. 3B). In this same analysis, we did not detect any difference in 
H3K9Ac between macrophages from T1D and nondiabetic mice in three tested regions of 
the STAT3 promoter (Fig. 3C), a gene that is not modulated in STZ-induced T1D (Fig 3D). 
Similarly, when we assessed another histone modification, H3K79 dimethylation, we found 
no differences between macrophages from T1D and nondiabetic mice (Fig. 3E and F). Thus, 
these results suggest that H3K9Ac on the MyD88 promoter is specifically associated with 
T1D.
Increased HAT activity in T1D mice leads to enhanced MyD88 and STAT1 expression in 
macrophages
We next sought to determine whether increased expression of MyD88 and STAT1 in 
macrophages from diabetic mice was a consequence of imbalanced HAT and HDAC activity 
that resulted in increased histone acetylation. Macrophages from nondiabetic and T1D mice 
were treated in vitro with the HAT inhibitor anacardic acid (Mai, Rotili et al. 2006). We 
found that anacardic acid treatment reduced mRNA (Fig. 4A and B) and protein (Fig. C) 
expression of Myd88 and Stat1 mRNA by T1D macrophages to normal levels. These results 
provide direct evidence that the increased expression of STAT1 and MyD88 in macrophages 
from T1D mice can be blocked by inhibiting H3K9Ac.
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Discussion
Epigenetic mechanisms are involved in inflammatory diseases such as arthritis and asthma 
(Ho 2010, Viatte, Plant et al. 2013). Here, we demonstrated an essential role of histone 
acetylation in the increased expression of MyD88 and STAT1 in macrophages from diabetic 
mice. Macrophages from diabetic mice presented increased HAT and decreased HDAC 
activity. Modulation of HAT and HDAC activity was associated with enhanced Myd88 and 
Stat1 gene expression. ChIP analysis showed that macrophages from diabetic mice presented 
acetylation in the promoter region of theses genes in H3K9. Moreover, when macrophages 
were treated with HAT inhibitor the gene expression of Myd88 and Stat1 was inhibited to 
the same level found in macrophages from non-diabetic animals.
An increasing body of evidence suggests that epigenetic modifications, subsequent to a 
priming event, are involved in reprogramming innate immune cells in normal and pathologic 
immune responses. Upon restimulation, macrophages exhibit enhanced responses, which 
boost host defense and inflammation, a process termed innate immune memory (Netea, Latz 
et al. 2015). In Alzheimer’s disease, there is evidence that chronic inflammation promotes 
innate reprogramming of microglia and astrocytes leading to uncontrolled NLRP3 activation 
and IL-1β production (Miao, Chen et al. 2014). Because diabetes is associated with chronic 
inflammation, it is to be expected that macrophages would be reprogramed, resulting in 
increased sterile inflammation.
The occurrence of chromatin modifications have been described in diabetes; these include 
H3K4 monomethylation in the promoter of p65 in response to hyperglycemia, which leads 
to increased expression of p65-responsive genes in endothelial cells (Reddy, Zhang et al. 
2015). In the present study, we found that T1D promoted H3K9Ac in the promoters of 
Myd88 and Stat1 in macrophages, leading to enhanced expression of these genes. This same 
epigenetic mark is found in COX-2 and TNF-a promoters in monocytes from diabetic 
patients (Reddy, Zhang et al. 2015). Moreover, monocytes from diabetic patients exhibit a 
higher than normal average number of regions enriched in H3K9Ac (Miao, Chen et al. 
2014). It was uncertain, however, whether this acetylation mark occurred in the promoter 
region of MyD88 and STAT1 in macrophages from people with diabetes patients.
The observation that culturing macrophages in low glucose medium did not restore Stat1/
Myd88 expression to normal levels indicates that their elevated expression is associated with 
metabolic memory. The concept of “metabolic memory” came from the observation that 
diabetic complications persist long after attainment of glycemic control. As a consequence 
of hyperglycemia and oxidative stress, epigenetic mechanisms that alter chromatin structure 
drive persistent gene expression, which results in long lasting chronic inflammation (Reddy, 
Zhang et al. 2015). These chromatin alterations associated with chronic inflammation are 
present in mature macrophages and in macrophage precursors in bone marrow.
Increased Stat1/Myd88 expression in T1D mice is associated with sterile inflammation, and 
several studies have shown that this inflammation is a primary cause of diabetes 
comorbidities (Filgueiras, Brandt et al. 2015, Filgueiras, Serezani et al. 2015). The fact that 
HAT inhibitor restored normal Stat1/Myd88 expression in macrophages from T1D mice 
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suggests that therapeutic strategies aimed at reducing Stat1/Myd88 expression in 
macrophages could provide a means to address diabetes comorbidities.
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Figure 1. 
Resident peritoneal macrophages from T1D mice and nondiabetic mice were cultured in low 
glucose (5 mM) for 6 days. At 2 and 6 day time points, Myd88 (A) and Stat1 (B) mRNA 
expression were determined by qPCR, and MyD88, STAT1, iNOS and actin protein 
expression were determined after 6 days of culture by immunoblotting (C). Blots shown are 
from one representative experiment (n=3). Bone marrow-derived macrophages from 
nondiabetic and T1D mice were differentiated in 5 mM or 25 mM of glucose, and Myd88 
(D) and Stat1 (E) expression was determined by qPCR. Bone marrow-derived macrophages 
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from nondiabetic were differentiated in low 5 mM or 25 mM of glucose or Data are 
expressed as mean ± SEM from at least 3 independent experiments; *p<0.05 compared to 
macrophages from nondiabetic mice or compared to macrophages differentiated from bone 
marrow of nondiabetic mice in 5 mM glucose.
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Figure 2. 
Activity of HAT and HDAC was analyzed in the nuclear fraction of peritoneal macrophages 
from T1D and nondiabetic mice as described in Materials and Methods (A). Macrophages 
from nondiabetic mice were cultured with or without TSA (10 µM) for 24 h, and Myd88 (B) 
and Stat1 (C) expression were determined by qPCR. Nondiabetic mice (n=4 mice per group) 
were treated in vivo with TSA (0.6 or 6 mg/Kg) for 24 h; resident peritoneal macrophages 
were harvested, and Myd88 (D) expression was determined by qPCR. Data are expressed as 
mean ± SEM from at least 3 independent experiments; *p<0.05 compared to macrophages 
from nondiabetic mice or compared to peritoneal macrophages isolated from vehicle treated 
cells.
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Figure 3. 
Formaldehyde-fixed chromatin from macrophages from T1D and nondiabetic mice was 
immunoprecipitated (IP) to enrich (A–C) H3K9Ac and (D, E) Di-Methyl H3K79 complex 
using specific antibodies followed by qPCR as described in Materials and Methods. Stat3 
expression was determined in macrophages from T1D mice and nondiabetic mice by qPCR 
(D). Data are expressed as means ± SEM from 3 independent experiments; *p<0.05 
compared to macrophages from nondiabetic mice.
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Figure 4. 
Macrophages from T1D mice (n=4) and nondiabetic mice (n=5) were cultured with or 
without anacardic acid (AA) for 24 h. Myd88 (A) and Stat1 (B) expression were determined 
by qPCR, and MyD88, STAT1 and actin protein expression were determined by 
immunoblotting (C). Immunoblots are shown from one representative experiment (n=3). 
Data are expressed as means ± SEM from 3 independent experiments; *p<0.05 compared to 
macrophages from nondiabetic mice.
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Table 1
Primers used for qPCR.
Gene Primer sequence
Hprt
F: AGCAGGTCAGCAAAGAACT
R: CCTCATGGACTGATTATGGACA
Myd88
F: TAGTCGCAGACAGTGATGAAC
R: CTGCAGAGCAAGGAATGTGA
Stat1
F: GACTTCAGACACAGAAATCAACTC
R: TTGACAAAGACCACGCCTT
Stat3
F: CATGTCAAACGTGAGCGACT
R: GGAAATAACGGTGAAGGTGCT
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Table 2
Primers used for ChIP on the murine Stat1 promoter.
Region Region in
murine Stat1
promoter
Primer sequence
P1 +52 to + 391
F: GCGCAAGCCTATAGTTTCCA
R: GTCTGGGCAAATCTCTCTGC
P2 +51 to +522
F: GCGCAAGCCTATAGTTTCCA
R: TCTCTCTGCGGGATGACAG
P3 −154 to −753
F: GTCAGTGGAGGTCCGAAGAG
R: CGAGTCTGGGCAAATCTCTC
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Table 3
Primers used for ChIP on the murine Myd88 promoter.
Region Region in
murine Myd88
promoter
Primer sequence
P1 −93 to + 81
F: CACAAGTGGGTTGACTTTTAGGCT
R: GGCAGGCAACCCTGGGCCCCCGG
P2 −569 to −280
F: AATAGATTAACCAAGTGAATTAA
R: TATTCTGGTAGTAGGGAGGGAAGAG
P3 −1053 to −877
F: GAAGGAGGTTTCCCAAACTTCTGGTT
R: ACCCGGGGCTGAGCACAGCAAA
J Diabetes Complications. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Filgueiras et al. Page 17
Table 4
Primers used for ChIP on the murine Stat3 promoter.
Region Region in
murine Stat3
promoter
Primer sequence
P1 −140 to −470
F: GGTGACACCTGGGGACCGCCTAAG
R: AAAAACGCCTCTAGGAGAGAAGGC
P2 cre binding
F: GGGGGAGGGAGGAGACATTA
R: GAGCCGTATCAGGGCATTTA
P3 −1600
F: CCATTGGGGGATTATCTTTG
R: TGGTGTTTGTATTGCTGGTGA
J Diabetes Complications. Author manuscript; available in PMC 2018 February 01.
